Literature DB >> 1346923

Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy.

H G Harley1, J D Brook, S A Rundle, S Crow, W Reardon, A J Buckler, P S Harper, D E Housman, D J Shaw.   

Abstract

Myotonic dystrophy is the commonest adult form of muscular dystrophy, with an estimated incidence of 1 per 7,500, although this is likely to be an underestimate because of the difficulty of detecting minimally affected individuals. It is a multisystem autosomal dominant disorder of unknown biochemical basis. No case of new mutation has been proven. We have isolated a human genomic clone that detects novel restriction fragments specific to individuals with myotonic dystrophy. A two-allele EcoRI polymorphism is seen in normal individuals, but in most affected individuals one of the normal alleles is replaced by a larger fragment, which varies in length both between unrelated affected individuals and within families. The unstable nature of this region may explain the characteristic variation in severity and age at onset of the disease. A second polymorphism at this locus is in almost complete linkage disequilibrium with myotonic dystrophy, strongly supporting our earlier results which indicated that most cases are descended from one original mutation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346923     DOI: 10.1038/355545a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  167 in total

1.  Mutagenic stress modulates the dynamics of CTG repeat instability associated with myotonic dystrophy type 1.

Authors:  Elisabeth Piñeiro; Laura Fernàndez-López; Josep Gamez; Ricard Marcos; Jordi Surrallés; Antonia Velázquez
Journal:  Nucleic Acids Res       Date:  2003-12-01       Impact factor: 16.971

Review 2.  Recent advances in understanding muscular dystrophy.

Authors:  K M Bushby
Journal:  Arch Dis Child       Date:  1992-10       Impact factor: 3.791

3.  Instability versus predictability: the molecular diagnosis of myotonic dystrophy.

Authors:  G K Suthers; S M Huson; K E Davies
Journal:  J Med Genet       Date:  1992-11       Impact factor: 6.318

4.  A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; D Teare; V Newton; T Strachan; R Ramsden; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

Review 5.  The Role of RNA in Biological Phase Separations.

Authors:  Marta M Fay; Paul J Anderson
Journal:  J Mol Biol       Date:  2018-05-10       Impact factor: 5.469

Review 6.  Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.

Authors:  Laura P W Ranum; John W Day
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

7.  Comparison of CTG repeat length expansion and clinical progression of myotonic dystrophy over a five year period.

Authors:  L Martorell; J M Martinez; N Carey; K Johnson; M Baiget
Journal:  J Med Genet       Date:  1995-08       Impact factor: 6.318

8.  Direct molecular analysis of myotonic dystrophy in the German population: important considerations in genetic counselling.

Authors:  A Meiner; C Wolf; N Carey; A Okitsu; K Johnson; P Shelbourne; B Kunath; W Sauermann; H Thiele; P Kupferling
Journal:  J Med Genet       Date:  1995-08       Impact factor: 6.318

9.  Molecular and clinical correlations in spinocerebellar ataxia type I: evidence for familial effects on the age at onset.

Authors:  L P Ranum; M Y Chung; S Banfi; A Bryer; L J Schut; R Ramesar; L A Duvick; A McCall; S H Subramony; L Goldfarb
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

10.  Myotonic dystrophy: correlation of clinical symptoms with the size of the CTG trinucleotide repeat.

Authors:  A Jaspert; R Fahsold; H Grehl; D Claus
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.